3,120 Shares in Glaukos Corporation $GKOS Acquired by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd has acquired 3,120 shares of Glaukos Corporation, valued at approximately $307,000, marking its entry into the stock during the 1st quarter.
• Several large investors, including Deutsche Bank AG and Lazard Asset Management LLC, have significantly increased their holdings in Glaukos during the previous quarter, enhancing institutional ownership to 99.04%.
• Glaukos reported earnings of ($0.24) per share for the last quarter, slightly beating analyst expectations, with a revenue increase of 29.7% year-over-year, while maintaining a negative net margin of 21.43%.

Dynamic Technology Lab Private Ltd bought a new position in Glaukos Corporation (NYSE:GKOS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,120 shares of the medical instruments supplier's stock, valued at approximately $307,000.

A number of other hedge funds have also added to or reduced their stakes in GKOS. Deutsche Bank AG lifted its holdings in shares of Glaukos by 49.6% in the fourth quarter. Deutsche Bank AG now owns 43,859 shares of the medical instruments supplier's stock worth $6,576,000 after buying an additional 14,540 shares in the last quarter. Focus Partners Wealth purchased a new stake in Glaukos in the 4th quarter worth approximately $379,000. Lazard Asset Management LLC boosted its holdings in Glaukos by 228.2% in the 4th quarter. Lazard Asset Management LLC now owns 13,911 shares of the medical instruments supplier's stock valued at $2,085,000 after purchasing an additional 9,673 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Glaukos by 3.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,349 shares of the medical instruments supplier's stock valued at $4,551,000 after purchasing an additional 984 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in shares of Glaukos by 0.9% in the fourth quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock worth $47,226,000 after purchasing an additional 2,665 shares during the period. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. William Blair raised Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. UBS Group raised their price target on Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Mizuho set a $130.00 price objective on shares of Glaukos in a research report on Thursday, July 31st. Zacks Research downgraded shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Wells Fargo & Company boosted their price target on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $124.83.

Glaukos Price Performance

GKOS traded down $2.04 during midday trading on Monday, hitting $80.72. The stock had a trading volume of 1,211,730 shares, compared to its average volume of 635,607. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The business has a fifty day moving average of $93.06 and a 200 day moving average of $95.22. The company has a market cap of $4.63 billion, a P/E ratio of -48.92 and a beta of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. During the same period last year, the firm posted ($0.52) earnings per share. The business's revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.